Skip to main content
CAI logo

CAI · Caris Life Sciences, Inc. · Documents

Track CAI — free
$17.58 -0.96 (-5.18%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$5.04B
Shares
286.78M
Volume · Nov 20 4.57M Avg daily vol (3M) 4.64M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $812.03M up 97.0% 10-K filed Mar 3, 2026 Quarterly report FY2026 Q3 Revenue $275.36M up 27.0% 10-Q filed Nov 4, 2026 Latest results Revenue up 27%, full-year 2026 guidance raised 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
Revenue rises 27% as full-year outlook is raised

Caris Life Sciences, Inc. reported third-quarter revenue of $275.4 million, up 27% year-over-year, with adjusted EBITDA of $44.4 million and GAAP net income of $15.3 million. Management raised full-year revenue guidance to $1.04 billion to $1.05 billion.

Read from the first part of this long document
4 source passages
We delivered another strong quarter with total revenue of $275.4 million, which is up 27% year-over-year, and brings our nine-month revenue to $755.2 million, which is up 45% year-to-date. Adjusted EBITDA was $44.4 million, our sixth consecutive positive quarter, compared with $51.2 million in the prior year, which again carried a larger true-up benefit. Year-to-date, adjusted EBITDA is $126.3 million, up from $31.7 million for the same nine months last year. These results produced GAAP net income of $15.3 million compared with $24.3 million a year ago. Finally, turning to guidance, given the strength of our first nine months, we're raising our full-year outlook range to approximately $1.04 billion to $1.05 billion, up from $1.03 to $1.04 billion, representing growth of approximately 28 to 29 percent, driven by molecular profiling Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 45.5%; net income reaches $14.1 million

Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.

Revenue $275.36M ▲ 27.0% Net income $15.25M ▼ 37.3% Diluted EPS $0.05 ▼ 37.5%
Read from the MD&A section
4 source passages
Total revenue was $755.2 million for the nine months ended September 30, 2026, compared to $519.1 million for the nine months ended September 30, 2025, an increase of $236.1 million, or 45.5%. For the nine months ended September 30, 2026 and 2025, we generated total revenue of $755.2 million and $519.1 million, respectively, and reported net income (loss) of $14.1 million and $(150.0) million, respectively. Total revenue was $275.4 million for the three months ended September 30, 2026, compared to $216.8 million for the three months ended September 30, 2025, an increase of $58.5 million, or 27.0%. For the three months ended September 30, 2026 and 2025, we generated total revenue of $275.4 million and $216.8 million, respectively, and reported net income of $15.3 million and $24.3 million, respectively. Open the document at this passage
Nov 4
Current report 8-K
Revenue up 27%, full-year 2026 guidance raised

Caris Life Sciences reported results for the quarter ended September 30, 2026: total revenue of $275.4 million, up 27%, and net income of $15.3 million. Full-year 2026 revenue guidance raised to $1.04 to $1.05 billion, growth of 28% to 29%.

Financial results
4 source passages
Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period. Reported net income of $15.3 million. Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025. Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $263.71M ▲ 45.4% Net loss $637K Diluted EPS $0.00
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $216.17M ▲ 78.8% Net loss $510K Diluted EPS $0.00
Apr 23
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $812.03M ▲ 97.0% Net loss $68.09M Diluted EPS -$3.22
2025
Showing 1–33 of 33 documents
Key facts CIK 2019410 CUSIP 142152107 13F (30d) 312 filings 296 filers Visit website Investor relations